Johnson & Johnson (J&J) has named Joaquin Duato as the company’s new CEO.
Duato currently serves as the vice-chairman of the company’s executive committee and will take over the role of CEO from Alex Gorsky, effective 3 January 2022. Following the transition of the CEO role, Duato will also be appointed as a member of the company’s board of directors.
During his 30+ year career at J&J, Duato has worked in multiple business sectors, geographies, and functions. As vice-chairman of the executive committee, he provides strategic direction for the pharmaceutical and consumer health sectors and oversees the global supply chain, technology, and health and wellness teams.
Gorsky said that while his decision to step aside was “one of the most difficult” in his career, this is the right time for change, as the company is delivering strong performance, and he will be able to focus more on his family.
“It has been an honour and a privilege to lead this company as chairman and CEO for nearly a decade,” said Gorsky, “and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere.”
Duato said he is “honoured” to serve as J&J’s next CEO, adding: “Our company has an unmatched healthcare platform: we are a global pharmaceutical leader with a robust pipeline of transformational and innovative medicines. Our medical device business is at the forefront of applying cutting-edge technology to deliver physician and patient-centric products and solutions, and our consumer health business continues to evolve its portfolio of iconic heritage brands and innovative growth brands.
“As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health.”